Moderna is an mRNA medicine company with three commercial products—Spikevax and mNEXSPIKE (COVID-19 vaccines) and mRESVIA (RSV vaccine)—generating $1.9B in total 2025 revenue, primarily from COVID vaccine sales. Its development pipeline spans oncology, including the individualized neoantigen therapy intismeran co-developed with Merck, as well as infectious disease vaccines and rare disease mRNA therapeutics for propionic acidemia and methylmalonic acidemia.
Moderna operates a global manufacturing network with company-built and managed facilities in the U.S., UK, Canada, and Australia. Regulatory submissions for flu and flu+COVID combination vaccine candidates are under review across multiple markets, and a strategic collaboration with Recordati was entered in January 2026 to advance the propionic acidemia program through late-stage development and commercialization.
US 62% · Rest Of World 36% · Europe 3%
geographic · FY2025 (ended Dec 2025) · share of tagged segment revenue (10-K XBRL, as filed)
